Accelerate Diagnostics Stock

Accelerate Diagnostics Equity

Delisted

The The Equity of Accelerate Diagnostics (AXDX) as of Sep 13, 2026 is -56.04 M USD. In the previous year, The Equity was -19.89 M USD — a change of 181.78% (lower).

Equity

-56.04 MUSD

YoY

181.78%

Last updated:

In 2026, Accelerate Diagnostics's equity was -56.04 M USD, a 181.78% increase from the -19.89 M USD equity in the previous year.

The Accelerate Diagnostics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
119.92 M USD
Jan 1, 2018
57.38 M USD
Jan 1, 2019
-7.38 M USD
Jan 1, 2020
-62.81 M USD
Jan 1, 2021
-35.07 M USD
Jan 1, 2022
-22.26 M USD
Jan 1, 2023
-19.89 M USD
Jan 1, 2024
-56.04 M USD
The Accelerate Diagnostics Equity history
YEAREquityYoY
-56.04 MUSD+181.78%
-19.89 MUSD-10.67%
-22.26 MUSD-36.52%
-35.07 MUSD-44.17%
-62.81 MUSD+751.23%
-7.38 MUSD-112.86%
57.38 MUSD-52.16%
119.92 MUSD+54.11%
77.82 MUSD-41.50%
133.02 MUSD+101.57%
65.99 MUSD—
Access this data via the Eulerpool API
Get Free API Key

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Accelerate Diagnostics's Equity

Accelerate Diagnostics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Accelerate Diagnostics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Accelerate Diagnostics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Accelerate Diagnostics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Accelerate Diagnostics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Accelerate Diagnostics stock

The Equity of Accelerate Diagnostics is -56.04 M USD in 2026.

The Equity of Accelerate Diagnostics changed from -19.89 M USD to -56.04 M USD, representing a 181.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Accelerate Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Accelerate Diagnostics